Difficulty and hot-points on pharmacokinetics studies of traditional Chinese medicine

Yaoxue Xuebao

Volumn 40, Issue 5, 2005, Pages 395-401

  Liu, Chang Xiao ^a  

^a TIANJIN INSTITUTE OF PHARMACEUTICAL RESEARCH   (China)

Author keywords

High throughput screening; Metabonomics; Pharmacokinetics; Traditional Chinese medicine

Indexed keywords

HERBACEOUS AGENT;

ANIMAL; ARTICLE; BIOTRANSFORMATION; CHEMISTRY; CHINESE MEDICINE; DRUG COMBINATION; HUMAN; ISOLATION AND PURIFICATION; MEDICINAL PLANT;

ANIMALS; BIOTRANSFORMATION; DRUG COMBINATIONS; DRUGS, CHINESE HERBAL; HUMANS; MEDICINE, CHINESE TRADITIONAL; PLANTS, MEDICINAL;

EID: 22244465859     PISSN: 05134870     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (51)

1. Chen QH. Absorption, excretion and distribution of derivatives of anthraquinone from Rheum, Chinese traditional medicines. Acta Pharm Sin, 1963,10(9):525-528.
2. Han GZ. Pharmacokinetics of Traditional Chinese Medicines [M]. Beijing: China Pharmaceutical Press, 1999.3-16.
3. Liu CX. Significance of pharmacokinetics in research and development of tradition Chinese medicines. Chin Tradit Herb Drugs, 2001,32:s16-17.
4. Liu CX, Xiao PG, Li DP. Modern Research of Chinese Medicinal Plants [M]. Hong Kong: Hong Kong Medical Publisher, 2000.
5. Xiao PG, Liu CX. Pharmacology, pharmacokinetics and toxicology of active constituents isolated from Ginkgo biloba L. Asia J Drug Metab Pharmacokinet, 2001, 1(3):229-232.
6. Xiao PG, Liu CX. Pharmacology, pharmacokinetics, toxicology and therapeutics of Radix Notoginseng. Asia J Drug Metab Pharmacokinet, 2001,1(1):70-76.
7. Liu CX, Xiao PG. Pharmacology, pharmacokinetics and toxicology of active constituents isolated from Radix Salviae multiorrhizae. Asia J Drug Metab Pharmacokinet, 2001,1(3):221-228.
8. Xiao PG, Liu CX. Pharmacology, pharmacokinetics, toxicology and clinical therapeutics of active constituents isolated from Berberis plant. Asian J Drug Metab Pharmacokinet, 2001,1(2):135-139.
9. Xiao PG, Liu CX. Pharmacology, pharmacokinetics and therapeutics of traditional Chinese medicine: Radix Glycyrrhiza. Asia J Drug Metab Pharmacokinet, 2001,1(2):140-150.
10. Yang CM, Hou SX, Zhang ZR. Recent advance in metabolic chemistry of traditional Chinese medicine. Asia J Drug Metab Pharmacokinet, 2001,1(1):57-62.
11. Liu YM, Chen H, Zeng FD. The advance in studies on pharmacokinetics of Ligustrazin in China. Asian J Drug Metab Pharmacokinet, 2001,1(3):217-220.
12. Sun LQ. Ethnopharmacology, pharmacology, pharmacokinetics, toxicology and therapeutics of Fructus Crataegi. Asia J Drug Metab Pharmacokinet, 2002,2(4): 291-297.
13. Liu CX. Pharmacokinetics studies in modern research of traditional Chinese medicines. International Seminar of Advanced Development of Traditional Chinese Medicine Modernization Research [R]. Tianjin: International College of Traditional Medicine, 2003.25-27.
14. Smolen VF, Barile RG, Theophanous TG. Relationships between dose, effect, time and biophasic drug levels. J Pharm Sci, 1972,61(3):467-470.
15. Fu HY, Ho YZ, Zhou AX. Perimary study on pharmacokinetics of Ma-huang-tang, Gui-zhi-tang, Ying-Qiao-san and Sang-Ju-yin by phamracodynamic method with antipyretic model. Pharmacol Clin Chin Mater Med, 1992,8(1):1-4.
16. Fu HY, Ho YZ, Zhou AX. Re-studies on pharmacokinetics of Ma-huang-tang, Gui-zhi-tang, Ying-Qiao-san and Sang-Ju-yin by phamracodynamic method with diaphoretic model. Pharmacol Clin Chin Mater Med, 1992,8(5):1-4.
17. Fu HY, Ho YZ, Zhou AX. Re-studies on pharmacokinetics of Ma-huang-tang, Gui-zhi-tang, Ying-Qiao-san and Sang-Ju-yin by phamracodynamic method with anti-inflammation model. Pharmacol Clin Chin Mater Med, 1993,9(2):1-4.
18. Fu HY, Zhou AX, Ho YZ. Re-studies of pharmacokinetics of Ma-huang-tang, Gui-zhi-tang, Ying-Qiao-san and Sang-Ju-yin by phamracodynamic method. J Chin Patent Drugs, 1993,15(1):35-38.
19. Hao MS, ZhanLM, Ge JY. Calcilation of half-life by death ratio method. Acta Pharmacol Sin, 1985,6(3):213-215.
20. Long SJ, Xu LB, Qiu Y. Determination of toxicokinetic parameters of Guan-mu-tong. Pharmacol Clin Chin Mater Med, 2003,19(1):19-22.
21. HuangYM, Pan LH, Wu XF. Study on toxicokinetics of Wu-tou ingjection in mice. J Chin Pharmaceut, 1998,33(7):421-423.
22. Tai TH, Liang CC. Pharmacokinetics of tetramethylpyrazine in rat blood and brain using microdialysis. Int J Pharmaceut, 2001,216:61-65.
23. Xiang QJ, Cheng G, Chen JM. Pharmacokinetic study of Shao-yao and Gan-cao decoctionin rats. J Chin Pharmaceut, 2000,30(4):384-386.
24. Yang K, Pu XF. On significance of gastroenterouos pharmacokinetics. Chin J Exper Rescript, 1998,4(1):36-39.
25. Hiroko I, Sakae A, Yukio O. Effect of shassaikoto, a Japanese and Chinese herbal medicinal mixture, on the mitogentic activity of Lipopolysaccharide.. A new pharmacological tesing method. J Ethnopharmacol, 1987,211(1):45-50.
26. Ma J, Tang Z, Li ZQ. Serum pharmacological application in pharmacokinetic studies of complex traditional Chinese medicines. Pharmacol Clin Chin Mater Med, 1999,15(1):44-48.
27. Huang X, Zhuang YM, Xia T. On "zheng"-knetics. Pharmacol Clin Chin Mater Med, 1994,14(6):43-46.
28. Huang X. The concepts of recipe-derived component spectrum and target component in vivo/serum and their significance. J Fourth Mil Med Univ, 1999,20(4):277-280.
29. Fugh-Berman A. Herb-drug interactions. Lancet, 2000,355(9198):134-138.
30. Fugh-Berman A. Herbal Supplements: Indications, Clinical Concerns, and Safety. Nutr Today, 2002, 37(3):122-124.
31. Fugh-Berman A, Ernst E. Herb-drug interactions: review and assessment of report reliability. Br J Clin Pharmacol, 2001,52(5):587-595.
32. Ernst E. Herb-drug interactions: potentially important but woefully under-researched. Eur J Clin Pharmacol, 2000,56(8):523-524.
33. Crespi CL, Gonzalez FJ, Steimel DT, et al. A metabolically competent human cell line expressing five cDNAs encoding procarcinogen-activating enzymes: application to mutagenicity testing. Chem Res Toxicol, 1991,4(5):566-572.
34. Jacobs BP, Browner WS. Ginkgo biloba: a living fossil. Am J Med, 2000,108(4):341-342(32).
35. Le Marchand L, Murphy SP, Hankin JH, et al. Intake of flavonoids and lung cancer. J Natl Cancer Inst, 2000,92(2):154-160.
36. Ishihara K, Kushida H, Yuzurihara M, et al. Interaction of drugs and Chinese herbs: pharmacokinetic changes of tolbutamide and diazepam caused by extract of Angelica dahurica. J Pharm Pharmacol, 2000,52(8): 1023-1029. (34)
37. Dresser GK, Bailey DG, Carruthers SG. Grapefruit juice-felodipine interaction in the elderly. Clin Pharmacol Ther, 2000,68(1):28-34(35).
38. Wrighton SA, VandenBranden M, Ring BJ. The human drug metabolizing cytochromes P450. J Pharmacokinet Biopharm, 1996,24(5):461-473(36).
39. Wrighton SA, VandenBranden M, Stevens JC, Shipley LA, Ring BJ, Rettie AE, Cashman JR In vitro methods for assessing human hepatic drug metabolism: their use in drug development. Drug Metab Rev, 1993,25(4): 453-484.
40. Awang DV, Fugh-Berman A. Herbal interactions with cardiovascular drugs. J Cardiovasc Nurs, 2002,16 (4):64-70.
41. Donovan JL, DeVane CL, Chavin KD, Taylor RM, Markowitz JS. Siberian ginseng (Elecutheroccus senticosus) effects on CYP2D6 and CYP3A4 activity in normal volunteers. Drug Metab Dispos, 2003,31 (5):519-522.
42. Chang TK, Chen J, Benetton SA. In vitro effect of standardized ginseng extracts and individual ginsenosides on the catalytic activity of human CYP1A1, CYP1A2, and CYP1B1. Drug Metab Dispos, 2002,30(4): 378-384.
43. Lee HC, Hwang SG, Lee YG, et al. In vivo effects of Panax ginseng extracts on the cytochrome P450-dependent monooxygenase system in the liver of 2, 3, 7, 8-tetrachlorodibenzo-p-dioxin-exposed guinea pig. Life Sci, 2000,71(7):759-769.
44. Fan HR, He F, Li QS, et al. Study on influence of ginsenoside Re on cytochrome P450 isoforms by cocktail approach using probe drugs, caffeine, chlorzoxazone, omeprazole and dapsone in rats. Asia J Drug Metab Pharmacokinet, 2004,4(3):177-186.
45. Yu LS, Zeng S. CY3A4 and P-glycoprotein in small intestinal epithelial cells and their affects to some oral drugs. Asia J Drug Metab Pharmacokinet, 2001,1 (4):305-312.
46. Hiroshi S, Yuchi S. Role of metabolic enzymes and efflux transporters in the absorption of drugs from the small intestine. Eur J Pharm Sci, 2000,12(1):3-12.
47. Lindon JC, Holmes E, Nicholson JK. So what's the deal with metabonomics?. Anal Chem, 2003,75(17): 384A-391A.
48. Liu CX, Li C, Lin DH, et al. Significance of metabonomics in drug discovery and development. Asia J Drug Metab Pharmacokinet, 2004,4(2):87-96.
49. Liu CX. Metabonomics in drug discovery and development [A]. He FC. New Drug Discovery in Postgene Time [M]. Beijnig: Beijing Military Medical Press, 2004. 17-20.
50. Liu CX. Significance of metabonomics in modern research of tradition Chinese medicines. Chin Tradit Herb Drugs, 2004,35(6):601-605.
51. Huang YR, Wei GL, Xiao SH, et al. Studies on pharmacodynamics and its biochemical mechanism of Ucncariastem mixture for treating children's hyperactivity syndrome by metabonomic method. Chin Tradit Herb Drugs, 2005,36(3):301-305.